About: Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.01 (-8.33%)
OPTASXOpthea Ltd
Loading watchlist status…
Opthea Ltd share price
OPT price activity
Last Price
Change (24hr)
AUD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
OPT price performance
-8,33%
5D
-15,38%
1M
-98,17%
YTD
-98,17%
1Y
OPT price fundamentals
N/A
Shares Issued
N/A
Earnings Per Share (EPS)
N/A
Dividends Per Share (DPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
AU-ASX rank
N/ASector Rank
N/Aquote.marketSignals